Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study  by Jia, Jing-Ying et al.
CURRENT THERAPEUTIC RESEARCH
VOLUME 71, NUMBER 4, AUGUST lora
Pharmacokinetics of Depside Salts From Salvia
miltiorrhiza in Healthy Chinese Volunteers:
A Randomized, Open-Label, Single-Dose Study
]ing-Ying ]ia, MSl; You-Li Lu, PhD2; Xiao-Chuan Li, PhD 2; Gang-Yi Liu, MSl;
Shui-jun Li, PhDl,2; Yun Liu, MDl; Yan-Mei Liu, MDl; Chen Yu, MSl; and
Yi-Ping Wang, PhD2
l Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China; and 2State Key
Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of
Sciences, Shanghai, China
ABSTRACT
BACKGROUND: Depside salts from Salvia miltiorrhiza, with active components
of Iirhosperrnic acid B (LSB), rosrnarinic acid (RA), and lithosperrnic acid (LA), are
a multicomponent drug marketed in China for the treatment of coronary heart
disease.
OBJECTIVES: The aims of this study were to determine the concentrations of
LSB, RA, and LA in human plasma and urine, and to compare the pharmacokinetic
properties of depside salts from S miltiorrhiza in healthy Chinese volunteers.
METHODS: A randomized, open-label, single-dose study was conducted in
healthy Chinese volunteers. Participants were randomly assigned to receive a single
intravenous infusion of 100 or 200 mg of depside salts from S miltiorrhiza. Blood was
collected through a venous cannula prior to study drug administration (0 min) and at 10,
20,30,60,65, 70, 80, and 90 minutes and 2, 3, 4, 6, 8, 12, and 24 hours after study
drug administration. Urine samples were taken before study drug administration (0)
and at °to 12 and 12 to 24 hours after study drug administration. LSB, RA, and LA
concentrations in serum and urine were analyzed by an LC-MS/MS method. Tolera-
bility was determined by clinical assessment; vital signs (ie, blood pressure, heart rate,
breathing rate, body temperature) monitoring at baseline and at the end of the study,
clinical laboratory tests (ie, hematology, blood biochemistry, hepatic function, renal
function, urinalysis), 12-lead ECG measurements, and physical examinations at base-
line and after completion of the study.
RESULTS: Twelve Chinese volunteers (6 males, 6 females; mean [SD} age,
25.2 [3.8} years; mean height, 165.7 [8.9} em; mean body mass index, 21.6 [2.5} kg/m 2)
were enrolled in the study. Peak plasma concentrations of LSB, RA and LA were ob-
served at 0.3 to 1 hour following the I-hour intravenous infusion, with respective
mean (SD) C
max
of 4925 (1861), 174 (61), and 361 (101) ng/mL for the 100-mg dose
and 10,285 (2259), 308 (77), and 674 (85) ng/mL for the 200-mg dose. The AUClast
values for LSB, RA, and LA were 4537 (1265), 129 (28), and 1229 (330) ng/mLlh,
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respectively, for the 100-mg dose and 10,426 (2589),260 (53), and 2792 (729) ng/mL/h
for the 200-mg dose. No significant difference in pharmacokinetic parameters was
observed between male and female subjects. Three metabolites were found in the
plasma with low concentrations. The urinary excretion recoveries ofLSB, RA, and LA
were 0.58% (0.42%), 25.21 % (20.61 %), and 10.02% (7.72%) for the 100-mg dose
and 0.38% (0.18%), 20.11 % (10.50%), and 6.34% (3.20%) for the 200-mg dose. No
adverse events were reported by the subjects or found by the investigators in the
analysis of vital signs, 12-lead ECG measurements, physical examinations, or clinical
laboratory tests.
CONCLUSIONS: Following single intravenous infusion of 100 or 200 mg of depside
salts from S miltiorrhiza to healthy Chinese subjects, no statistical differences in
pharmacokinetic parameters were observed between males and females. The 2 doses
of depside salts from S miltiorrhiza were clinically well tolerated during the study.
(Curr Ther Res Clin Exp. 2010;71:260-271) © 2010 Excerpta Medica Inc.
KEY WORDS: lithospermic acid B, rosmarinic acid, lithospermic acid, pharmaco-
kinetics, healthy volunteers, liquid chromatography tandem mass spectrometry,
LC-MS/MS.
INTRODUCTION
Depside salts from Salvia miltiorrhiza are a multicomponent drug used for the
treatment of coronary heart disease. It was approved in 2005 by the State Food and
Drug Administration (SFDA) of China as an injection. These components are de-
rived from danshen, the dried roots of the medicinal plant S miltiorrhiza, a tradi-
tional Chinese medicine used for the treatment of hepatitis, blood circulation dis-
eases, and other cardiovascular diseases.' Lithospermic acid B (LSB) and its
analogues, rosmarinic acid (RA), and lithospermic acid (LA), are the main active
components of depside salts from S miltiorrbiza? Depside salts from S miltiorrhiza
have been reported to improve myocardial microperfusion and cardiac output in
rats.> LSB, also known as magnesium lithospermate B (MLB), is a strong antioxi-
dant and free radical scavenger extracted from S miltiorrhiza.4 ,5 Pharmacologic stud-
ies have indicated that MLB might protect against renal dysfunction, myocardial
damage, and experimental heparitis.v "! RA and LA are natural polyphenols with
antioxidative, antibacterial, and antiviral activities.V A 2009 study indicated that
LA was associated with inhibited vascular smooth muscle cell migration and prolif-
eration in rats.l ' A clinical study found that intravenous infusion of depside salts
from S miltiorrhiza was an efficacious treatment for coronary heart disease and an-
gina pectoris with heart-blood stagnation syndrome.l?
MLB is a component with oral absolute bioavailability of 0.0002 from the
AVC values after both intravenous and oral administration in ratsl? and is rapidly
excreted into the bile, mostly as methylated rnetabolires.l" The elimination t 1l2
for LSB, RA, and LA is 1.04,0.75, and 2.0 hours, respectively, in rats/ and 0.71, 0.51,
and 0.83 hour in dogs,17 following intravenous administration of depside salts from
S miltiorrhiza.
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This study aimed to investigate the pharmacokinetic (PK) parameters ofLSB, RA,
and LA after intravenous infusion of depside salts from S miltiorrhiza in healthy
Chinese subjects.
SUBJECTS AND METHODS
STUDY DESIGN
A randomized, open-label, single-dose study design was conducted in healthy male
and female volunteers at the Shanghai Xuhui Central Hospital (Shanghai, China). The
study was approved by the ethics committee of Shanghai Xuhui Central Hospital, and
carried out in accordance with Chinese ethical guidelines for biomedical research on
human subjects. Informed written consent was obtained from all volunteers prior to
study initiation. Medical history, physical examination results (including vital signs
and 12-lead ECG), and analyses of laboratory parameters (including complete blood
count, differential cell count, liver and renal function tests, and urinalysis) were re-
corded no more than 28 days prior to the commencement of the study. Subjects were
to be nonsmokers, with no history of alcohol abuse, or family history of diabetes mel-
litus. Subjects had to have not taken medication or consumed alcohol for ;::2 weeks
prior to the study and during the study period. They were allowed to engage in nor-
mal activities but were instructed to avoid severe physical exertion. Volunteers were
recruited through an advertisement and compensated for their participation.
Individuals were randomly divided evenly into 2 groups with random number ta-
ble and each group received either a 100- or 200-mg intravenous dose of depside salts
from S miltiorrhiza, in accordance with a predetermined schedule (dose amount, meal
timing, and sample collection). In each group, depside salts from S miltiorrhiza (LSB
~87.7%, RA ~4.5%, and LA ~0.9%) were dissolved in 250 mL of glucose solution
(5%) and intravenously infused at a flow rate of 250 mLlh for 1 hour.
A standardized meal was served to all subjects at 4, 6, and 12 hours after the I-hour
intravenous infusion. Venous blood samples (4 mL) were collected through a venous
cannula prior to study drug administration (0) and at 10,20, 30,60,65, 70, 80, and
90 minures and 2, 3, 4, 6, 8, 12, and 24 hours after study drug administration. The
actual collection time of each blood sample and any protocol deviations were recorded.
To obtain plasma, blood samples were heparinized and centrifuged at 3000 rpm for
10 minutes as soon as possible.
Fractionated urine samples were collected to measure the urinary excretion levels
of both groups before and after dosing at the following time points: before study drug
administration (0), 0 to 12 hours, and 12 to 24 hours after infusion.
Both plasma and urine samples were stored in labeled tubes at -80aC until
analysis.
CHEMICALS AND REAGENTS
Depside salts from S miltiorrhiza (l00 or 200 mg) were provided by Green Valley
Co. Ltd. (Shanghai, China). MLB, RA, LA, and silibinin (internal standard [IS}) were
provided by the Department of Phytochemistry, Shanghai Institute of Materia Medica,
Chinese Academy of Sciences (Shanghai, China). The purity of these compounds was
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verified to be >99% by using a validated HPLC method. HPLC-grade acetonitrile
and methanol were purchased from Fisher Scientific Co. (Fair Lawn, New Jersey).
Double-distilled water was used for the preparation of all solutions. All other reagents
were of analytic grade and used as received.
LIQUID CHROMATOGRAPHY MASS SPECTROMETRY
Plasma and urine samples were analyzed by LC-MS/MS as previously described.i
The system was composed of an HPLC (Shimadzu, Japan) coupled to a triple-quadruple
mass spectrometer (Perkin-Elmer API-3000, Sciex,Concord, Ontario, Canada) equipped
with an electrospray ionization source. The separation was achieved using a 5-J.lm C18
column (Capcell Pak, 50 x 2.0 mm internal diameter; Shiseido, Japan) with the mo-
bile phase of 60% water (containing 0.5% formic acid) and 40% acetonitrile. The
negative ionization mode was selected for the determination and the mass spectrom-
eter was operated in the multiple reaction monitoring mode, with monitoring of the
precursor-to-product ion transitions of mlz 717---+519 for LSB, mlz 359---+160 for
RA, m/z 537---+493 for LA, mlz 731---+533 for metabolite M1, mlz 745---+547 for M2,
mlz 759---+547 for M3, and mlz 481---+301 for silibinin (IS). These samples were iso-
lated by the same liquid-liquid extraction method as previously described. 16 Linear
ranges of calibration curves were 8 to 2048 ng/mL for all analytes with a lower limit
of quantitat ion of 8 ng/mL.
PHARMACOKINETIC ANALYSIS
PK analysis was performed for plasma concentrations of each compound using
Drug and Statistics, version 2.0 (Anhui Provincial Center for Drug Clinical Evalua-
tion, Anhui, China). The AUC from 0 to 24 hours (AUC1ast) ' Cmax' T max' mean resi-
dence time (MRT), and plasma elimination t 1l2 were calculated. Actual sampling
times were used in the calculation of these parameters.
TOLERABILITY ASSESSMENTS
Throughout the study, subjects were monitored by 2 investigators (YL. and Y-M.L.).
Tolerability was determined by clinical assessment; vital signs (ie, blood pressure, heart
rate, breathing rate, body temperature) monitoring at baselineand at the end of the study,
clinical laboratory tests (ie, hematology, blood biochemistry, hepatic function, renal func-
tion, urinalysis), 12-lead ECG measurements, and physical examinations were performed
at baseline and after completion of the study. Adverse events (AEs) were assessed at the
time of each blood draw using direct observation, spontaneous reporting, and nonspecific
questioning. All AEs and serious AEs were recorded on the case-report form. All clinical
laboratory tests were performed at the laboratory of Shanghai Xuhui Central Hospital,
which is accredited by the National Center for Clinical Laboratories of China (which
regularly tests and certifies laboratory testing facilities).
STATISTICAL ANALYSIS
A 2-tailed t test was used to compare the PK parameters (Cmax' Tmax' t 1/2, MRT, and
AUC1ast) between male and female subjects. P < 0.05 was considered to be statistically
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significant. Descriptive data were reported as mean (SD). All statistical analyses were
conducted using SPSS version 11.5 (SPSS Inc., Chicago, Illinois).
RESULTS
A total of 12 healthy Chinese subjects (6 males, 6 females; mean [SD} age, 25.2
D.8} years; mean height, 165.7 [8.9} em; mean body mass index, 21.6 [2.5} kg/m2)
were enrolled in the study. Baseline characteristics for the included participants are
summarized in Table 1.
PHARMACOKINETIC ANALYSIS
Mean plasma concentration-time profiles for LSB, RA, and LA after intravenous
infusion of 100 and 200 mg of depside salts from S miltiorrhiza are shown in Figure 1.
Mean values of the PK parameters for LSB, RA, and LA are summarized in
Table II. Peak plasma concentrations ofLSB, with mean concentrations of 4925 ng/mL at
the 100-mg dose and 10,285 ng/mL at the 200-mg dose, were observed after -0.7 hour
during the l-hour intravenous infusion with steady high plasma concentrations reached at
0.3 to 1 hour. There was a rapid decline in plasma concentrations immediately after the
I-hour infusion. The mean t 1I2for LSBranged from 2.3 to 2.9 hours. The mean C
max
value
for RA (308 ng/mL) was significantly lower than those for LA (674 ng/mL) and LSB
(10,285 ng/mL) after administration of the 200-mg dose, and the t1l2 for RA (0.58 h) was
also significantly lower than those for LA (5.48 h) and LSB(2.87 h).
The overall pattern of the plasma concentration-time profiles for LSB, RA, and LA
was not significantly different between all individuals in the 2 dose groups. Mean
C
max
and ADC lasr values for LSB, RA, and LA were 1.77 to 2.30 times higher when
the dose increased from 100 to 200 mg, whereas there were no significant increases in
Tmax' t 1/2, and MRT values for LSB, RA, and LA (Table II).
Table I. Baseline characteristics for included participants.* Data are mean (SD).
Variable
Age,y
Height, em
Weight, kg
BMI, kg/m2
Body temperature, °C
Heart rate, beats/min
Respiration, breaths/min
SBP, mm Hg
DBP, mm Hg
Male (n = 6)
26.3 (3.8)
170.2 (5.4)
64.2 (5.4)
22.0 (2.5)
36.8 (0.3)
78.3 (11.5)
16.3 (0.7)
116.6 (15.3)
76.8 (8.7)
Female (n = 6)
24.4 (3.5)
160.6 (5.6)
52.3 (5.3)
20.8 (2.3)
36.5 (0.3)
82.2 (12.3)
16.5 (0.8)
116.1 (14.3)
74.5 (8.9)
Total (N = 12)
25.2 (3.8)
165.7 (8.9)
58.2 (7.8)
21.6 (2.5)
36.7 (0.3)
80.6 (10.4)
16.4 (0.6)
116.4 (16.2)
75.4 (10.2)
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure.
*There were no statistically significant differences observed between males and females.
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Figure 1. Mean plasma concentration-time profiles of (A) Iithospermic acid B (LSB),
(B) rosmarinicacid (RA), and (C) Iithospermic acid (LA) atter intravenous infusion
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Results of the t test (Table III) indicated that the values of primary PK parameters
(C
max
' T max' t 1/2, MRT, and ADClast) were not statistically different for male and
female subjects in either dose group. With the exception of the t 1l2 in RA after a
100-mg dose (P = 0.04), all comparisons between males and females showed no sig-
nificant differences.
METABOLISM AND URINARY EXCRETION
Metabolite plasma PK data were assessed after intravenous infusion of each dose
level. Mean plasma concentration-time profiles for the metabolites Ml, M2, and
M3 after intravenous infusion at the 2 dose levels are shown in Figure 2. Pharma-
cokinetic parameters of M1, M2, and M3 in healthy subjects are summarized in
Table IV. For the 200-mg dose, the mean C
max
values for Ml, M2, and M3 were
173,168, and 106 ng/mL, respectively, and the ADC last values were 162, 187, and
159 ng/mLih.
The urinary excretion levels of LSB, RA, and LA during the 24 hours after intra-
venous administration are shown in Table V for both doses. The urinary excretion
was 0.58% for LSB and 10.02% for LA. RA is a small-molecule analogue of LSB,
and had urinary excretion of25.21 %. The concentrations ofRA and LSB in the urine
rapidly decreased during the 0- to 12-hour period after dosing. During the 12- to
24-hour period, RA and LSB were undetectable and LA was only 31.13 ng/mL in the
unne.
TOLERABILITY
The 2 doses of depside salts from S miltiorrhiza appeared to be well tolerated in the
population investigated. No AEs were reponed by the subjects or found by the inves-
tigators in the analysis of vital signs, 12-lead ECG measurements, physical examina-
tions, or clinical laboratory tests.
Table III. Group difference of pharmacokinetic parameters between male and female
subjects after administration of 100- or 200-mg doses (N = 12). Data are
P values.
Analyte Cmax Tmax t 1/ 2 MRT AUClast
100-mg Dose
LSB 0.10 0.17 0.85 0.32 0.30
RA 0.40 0.15 0.04 0.21 0.84
LA 0.27 0.93 0.78 0.14 0.57
200-mg Dose
LSB 0.78 1.00 0.74 0.63 0.41
RA 0.19 0.44 0.50 0.64 0.16
LA 0.29 0.17 0.41 0.60 0.88
MRT = mean residence time; AUClast = AUC from 0 to 24 hours; LSB = lithospermic acid B; RA =
rosmarinic acid; LA = lithospermic acid.
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Figure 2. Mean plasma concentration-time profiles of metabolites M1, M2, and M3 after
intravenous infusion of 100 or 200 mg of depside salts from Salvia miltiorrhiza
in healthy individuals (N =12).
Table IV. Pharmacokinetic parameters of metabolites M1, M2, and M3 after intravenous
infusion of 100 or 200 mg of depside salts from Salvia mi/tiorrhlza in healthy
subjects (N =12). Data are mean (SO).
Crnax ' Trnax' t1/ 2 , MRT, AUClast '
Metabolite ng/rnl, h h h ng/mL/h
100-mg Dose
Ml 49 (33) 0.70 (0.27) 0.49 (0.11) 1.06 (0.15) 56 (38)
M2 66 (34) 0.70 (0.27) 0.61 (0.45) 1.04 (0.08) 77 (45)
M3 74 (39) 0.93 (0.25) 0.63 (0.19) 1.13 (0.14) 93 (53)
200-mg Dose
M1 173 (51) 0.63 (0.25) 0.52 (0.21) 0.98 (0.12) 162 (59)
M2 168 (62) 0.75 (0.29) 0.52 (0.19) 1.01 (0.08) 187 (79)
M3 106 (52) 1.04 (0.08) 0.60 (0.14) 1.17 (0.05) 159 (90)
MRT = mean residence time; AUC1as! = AUC from 0 to 24 hours.
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Table V. The urinary excretion of Iithospermic acid B (L5B), rosmarinic acid (RA), and
Iithospermic acid (LA) during24 hours after intravenous administration of 100 or
200 mg of depside salts from Salvia mlltlorrhiza in healthy sUbjects (N =12).
Data are mean (SO).
Excretion Amount, mg Excretion Recovery, %
Component 100 mg 200 mg 100 mg 200 rng
LSB 0.51 (0.37) 0.67 (0.31) 0.58 (0.42) 0.38 (0.18)
RA 1.13 (0.93) 1.81 (0.95) 25.21 (20.61) 20.11 (10.50)
LA 0.09 (0.07) 0.11 (0.06) 10.02 (7.72) 6.34 (3.20)
DISCUSSION
A previous study indicated that LSB, RA, and LA are rapidly eliminated from the
serum and distributed widely after intravenous administration of depside salts from
S miltiorrhiza in rats.r' In clinical practice, 1-hour intravenous infusion is used to ob-
tain steady high plasma concentrations and prolong the t1l2 of L5B, RA, and LA. In
this study, steady high plasma concentrations were obtained during the I-hour intra-
venous infusion, followed by a rapid decline in plasma concentrations immediately
after the infusion. When the dose of depside salts from S miltiorrhiza was increased
from 100 to 200 mg, the elimination t 1l2 was also increased from 2.33 to 2.87 hours
for LSB, from 0.23 to 0.58 hour for RA, and from 3.74 to 5.48 hours for LA; however,
the differences were not statistically significant.
RA was eliminated more rapidly than LSB and LA, with the plasma concentration
decreasing to less than the lower limit of quanritarion within 3 hours of dosing. The
ADelasr value of LSB was much greater than those of RA and LA, which is in agree-
ment with the high amount ofLSB (87.7%) in depside salts from S miltiorrhiza. Al-
though only 0.9%, the ADCla" value for LA was -20% of the total AUC value. This
may be owing to the long t1/2 of LA.
Based on the PK parameters (C
max
' Tmax' t 1l2, MRT, AUClasr) between the sexes
investigated in the present study, no significant difference was found between men
and women; however, there was a significance (P = 0.04) observed in the t 1/2 for RA
at the 1Ou-rng dose that may not be clinically significant.
Comparison of LSB and the metabolite PK parameters for both groups suggested
that the C
max
and AUC values of the metabolites were much lower than those of the
parent drug LSB. These results are not statistically different from those found in rats,
because LSB is methylated rapidly in liver and most of the metabolites (M1, M2, and
M3) were excreted directly into bile and finally into feces.? The low urinary excretion
of LSB (0.58%) also indicated that renal secretion is not the main excretion
pathway.
LIMITATIONS
The study was conducted in a small population of healthy Chinese adult subjects with
a single dose administered. The PK characteristics of depside salts from S miltiorrhiza
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might differ in other populations. As the study was designed without a sample-size
analysis performed a priori, there is a possibility of a Type II error when no statistically
significant differences between the sexes are found. Because there was no correction for
multiple comparisons, there is a possibility of false-positive findings.
CONCLUSIONS
In this study of healthy Chinese adult male and female volunteers, there were no sig-
nificant differences observed in the PK parameters of LSB and LA after a single intra-
venous infusion of depside salts from S miltiorrhiza at a dose of 100 or 200 mg. Both
doses were generally well tolerated in this population.
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